Abstract
β-Lactams represent perhaps the most important class of antibiotics yet discovered. However, despite many years of active research, none of the currently approved drugs in this class combine oral activity with long duration of action. Recent developments suggest that new β-lactam antibiotics with such a profile would have utility in the treatment of tuberculosis. Consequently, the historical β-lactam pharmacokinetic data have been compiled and analyzed to identify possible directions and drug discovery strategies aimed toward new β-lactam antibiotics with this profile.
Keywords:
M. tuberculosis; carbapenem; cephalosporin; penicillin; pharmacokinetics; β-lactam.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Oral
-
Animals
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / classification
-
Anti-Bacterial Agents / pharmacokinetics*
-
Anti-Bacterial Agents / therapeutic use*
-
Biological Availability
-
Cell Membrane Permeability / drug effects
-
Drug Discovery / methods*
-
Half-Life
-
Haplorhini
-
Humans
-
Mycobacterium tuberculosis / drug effects*
-
Protein Binding
-
Retrospective Studies
-
Solubility
-
Treatment Outcome
-
Tuberculosis / drug therapy*
-
beta-Lactams / administration & dosage
-
beta-Lactams / classification
-
beta-Lactams / pharmacokinetics*
-
beta-Lactams / therapeutic use*
Substances
-
Anti-Bacterial Agents
-
beta-Lactams